Eli Lilly | LLY - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 43.1B 1.46B 2026-09
Abbott USD 16.15B 1.66B 2026-09
ALKERMES USD 651.93M 10.16M 2026-09
Amgen USD 23.23B 2.27B 2026-09
AstraZeneca USD 31.27B 286M 2026-09
Baxter International USD 3.81B 218M 2026-09
Biogen USD 3.9B 18.7M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Coherus Biosciences USD 75.51M 56.82M 2026-06
Drreddys Laboratories INR 154.49B 13.08B 2026-09
Eli Lilly USD 47B 745M 2026-09
Gilead Sciences USD 12B 982M 2026-09
GlaxoSmithKline GBP 20.72B 814M 2026-09
Glaxosmithkline GBP 20.72B 1.71B 2026-09
J&J USD 55.46B 562M 2026-09
Medtronic USD 11.8B 141M 2026-06
Merck USD 28.8B 1.07B 2026-09
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Novartis USD 32.52B 777M 2026-09
Novartis USD 32.52B 1.15B 2026-09
Novo Nordisk DKK 239.08B 13.92B 2026-06
Perrigo USD 1.02B 34.4M 2026-09
Pfizer USD 31.73B 920M 2026-09
Phibro Animal Health USD 295.79M 20.68M 2026-09
Prestige Brands USD 168.5M 14.7M 2026-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 29.77B 2.16B 2026-09
Sanofi EUR 31.93B 1.92B 2026-06
United Therapeutics USD 624.3M 16.5M 2026-09
Zoetis USD 2.68B 621M 2026-09